Drug combo battle: can extra medication save failing kidney transplants?
NCT ID NCT03737136
Summary
This study tested whether adding the drug bortezomib to standard treatment helps control rejection in kidney transplant patients. Twenty patients whose bodies were attacking their new kidneys were split into two groups: one got standard care, the other got standard care plus bortezomib. Researchers compared how well the transplanted kidneys functioned and whether harmful antibodies decreased over six months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIBODY-MEDIATED REJECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
SBMU
Tehran, Iran
Conditions
Explore the condition pages connected to this study.